The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations

George R. Washko*, Vincent S. Fan, Scott D. Ramsey, Zab Mohsenifar, Fernando Martinez, Barry J. Make, Frank C. Sciurba, Gerald J. Criner, Omar Minai, Malcolm M. DeCamp, John J. Reilly

*Corresponding author for this work

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Rationale: Lung volume reduction surgery (LVRS) has been demonstrated to provide a functionalandmortalitybenefitto a selectgroup of subjects with chronic obstructive pulmonary disease (COPD). The effect of LVRS on COPD exacerbations has not been as extensively studied, and whether improvement in postoperative lung function alters the risk of disease exacerbations is not known. Objectives: To examine the effect, and mechanism of potential benefit, of LVRS on COPD exacerbations by comparing the medical and surgical cohorts of the National Emphysema Treatment Trial (NETT). Methods: A COPD exacerbation was defined using Centers for Medicare and Medicaid Services data and International Classification of Diseases, Ninth Revision, discharge diagnosis. Measurements and Main Results: There was no difference in exacerbation rate or time to first exacerbation between the medical and surgical cohorts during the year before study randomization (P = 0.58 and 0.85, respectively). Postrandomization, the surgical cohort experienced an approximate 30% reduction in exacerbation frequency (P = 0.0005). This effect was greatest in those subjects with the largest postoperative improvement in FEV1 (P = 0.04) when controlling for changes in other spirometric measures of lung function, lung capacities, and roomair arterial blood gas tensions. Finally, LVRS increased the time to first exacerbation in both those subjects with and those without a prior history of exacerbations (P = 0.0002 and P < 0.0001, respectively). Conclusions: LVRS reduces the frequency of COPD exacerbations and increases the time to first exacerbation. One explanation for this benefit may be the postoperative improvement in lung function. Clinical trial registered with www.clinicaltrials.gov (NCT 00000606).

Original languageEnglish (US)
Pages (from-to)164-169
Number of pages6
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume177
Issue number2
DOIs
StatePublished - Jan 15 2008

Fingerprint

Pneumonectomy
Chronic Obstructive Pulmonary Disease
Disease Progression
Lung
Lung Volume Measurements
Centers for Medicare and Medicaid Services (U.S.)
Emphysema
International Classification of Diseases
Random Allocation
Gases
Clinical Trials

Keywords

  • COPD
  • Exacerbation
  • LVRS

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Washko, G. R., Fan, V. S., Ramsey, S. D., Mohsenifar, Z., Martinez, F., Make, B. J., ... Reilly, J. J. (2008). The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. American Journal of Respiratory and Critical Care Medicine, 177(2), 164-169. https://doi.org/10.1164/rccm.200708-1194OC
Washko, George R. ; Fan, Vincent S. ; Ramsey, Scott D. ; Mohsenifar, Zab ; Martinez, Fernando ; Make, Barry J. ; Sciurba, Frank C. ; Criner, Gerald J. ; Minai, Omar ; DeCamp, Malcolm M. ; Reilly, John J. / The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. In: American Journal of Respiratory and Critical Care Medicine. 2008 ; Vol. 177, No. 2. pp. 164-169.
@article{f5f72ec0a3584e63a1de16932b4de8c0,
title = "The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations",
abstract = "Rationale: Lung volume reduction surgery (LVRS) has been demonstrated to provide a functionalandmortalitybenefitto a selectgroup of subjects with chronic obstructive pulmonary disease (COPD). The effect of LVRS on COPD exacerbations has not been as extensively studied, and whether improvement in postoperative lung function alters the risk of disease exacerbations is not known. Objectives: To examine the effect, and mechanism of potential benefit, of LVRS on COPD exacerbations by comparing the medical and surgical cohorts of the National Emphysema Treatment Trial (NETT). Methods: A COPD exacerbation was defined using Centers for Medicare and Medicaid Services data and International Classification of Diseases, Ninth Revision, discharge diagnosis. Measurements and Main Results: There was no difference in exacerbation rate or time to first exacerbation between the medical and surgical cohorts during the year before study randomization (P = 0.58 and 0.85, respectively). Postrandomization, the surgical cohort experienced an approximate 30{\%} reduction in exacerbation frequency (P = 0.0005). This effect was greatest in those subjects with the largest postoperative improvement in FEV1 (P = 0.04) when controlling for changes in other spirometric measures of lung function, lung capacities, and roomair arterial blood gas tensions. Finally, LVRS increased the time to first exacerbation in both those subjects with and those without a prior history of exacerbations (P = 0.0002 and P < 0.0001, respectively). Conclusions: LVRS reduces the frequency of COPD exacerbations and increases the time to first exacerbation. One explanation for this benefit may be the postoperative improvement in lung function. Clinical trial registered with www.clinicaltrials.gov (NCT 00000606).",
keywords = "COPD, Exacerbation, LVRS",
author = "Washko, {George R.} and Fan, {Vincent S.} and Ramsey, {Scott D.} and Zab Mohsenifar and Fernando Martinez and Make, {Barry J.} and Sciurba, {Frank C.} and Criner, {Gerald J.} and Omar Minai and DeCamp, {Malcolm M.} and Reilly, {John J.}",
year = "2008",
month = "1",
day = "15",
doi = "10.1164/rccm.200708-1194OC",
language = "English (US)",
volume = "177",
pages = "164--169",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "2",

}

Washko, GR, Fan, VS, Ramsey, SD, Mohsenifar, Z, Martinez, F, Make, BJ, Sciurba, FC, Criner, GJ, Minai, O, DeCamp, MM & Reilly, JJ 2008, 'The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations', American Journal of Respiratory and Critical Care Medicine, vol. 177, no. 2, pp. 164-169. https://doi.org/10.1164/rccm.200708-1194OC

The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. / Washko, George R.; Fan, Vincent S.; Ramsey, Scott D.; Mohsenifar, Zab; Martinez, Fernando; Make, Barry J.; Sciurba, Frank C.; Criner, Gerald J.; Minai, Omar; DeCamp, Malcolm M.; Reilly, John J.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 177, No. 2, 15.01.2008, p. 164-169.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations

AU - Washko, George R.

AU - Fan, Vincent S.

AU - Ramsey, Scott D.

AU - Mohsenifar, Zab

AU - Martinez, Fernando

AU - Make, Barry J.

AU - Sciurba, Frank C.

AU - Criner, Gerald J.

AU - Minai, Omar

AU - DeCamp, Malcolm M.

AU - Reilly, John J.

PY - 2008/1/15

Y1 - 2008/1/15

N2 - Rationale: Lung volume reduction surgery (LVRS) has been demonstrated to provide a functionalandmortalitybenefitto a selectgroup of subjects with chronic obstructive pulmonary disease (COPD). The effect of LVRS on COPD exacerbations has not been as extensively studied, and whether improvement in postoperative lung function alters the risk of disease exacerbations is not known. Objectives: To examine the effect, and mechanism of potential benefit, of LVRS on COPD exacerbations by comparing the medical and surgical cohorts of the National Emphysema Treatment Trial (NETT). Methods: A COPD exacerbation was defined using Centers for Medicare and Medicaid Services data and International Classification of Diseases, Ninth Revision, discharge diagnosis. Measurements and Main Results: There was no difference in exacerbation rate or time to first exacerbation between the medical and surgical cohorts during the year before study randomization (P = 0.58 and 0.85, respectively). Postrandomization, the surgical cohort experienced an approximate 30% reduction in exacerbation frequency (P = 0.0005). This effect was greatest in those subjects with the largest postoperative improvement in FEV1 (P = 0.04) when controlling for changes in other spirometric measures of lung function, lung capacities, and roomair arterial blood gas tensions. Finally, LVRS increased the time to first exacerbation in both those subjects with and those without a prior history of exacerbations (P = 0.0002 and P < 0.0001, respectively). Conclusions: LVRS reduces the frequency of COPD exacerbations and increases the time to first exacerbation. One explanation for this benefit may be the postoperative improvement in lung function. Clinical trial registered with www.clinicaltrials.gov (NCT 00000606).

AB - Rationale: Lung volume reduction surgery (LVRS) has been demonstrated to provide a functionalandmortalitybenefitto a selectgroup of subjects with chronic obstructive pulmonary disease (COPD). The effect of LVRS on COPD exacerbations has not been as extensively studied, and whether improvement in postoperative lung function alters the risk of disease exacerbations is not known. Objectives: To examine the effect, and mechanism of potential benefit, of LVRS on COPD exacerbations by comparing the medical and surgical cohorts of the National Emphysema Treatment Trial (NETT). Methods: A COPD exacerbation was defined using Centers for Medicare and Medicaid Services data and International Classification of Diseases, Ninth Revision, discharge diagnosis. Measurements and Main Results: There was no difference in exacerbation rate or time to first exacerbation between the medical and surgical cohorts during the year before study randomization (P = 0.58 and 0.85, respectively). Postrandomization, the surgical cohort experienced an approximate 30% reduction in exacerbation frequency (P = 0.0005). This effect was greatest in those subjects with the largest postoperative improvement in FEV1 (P = 0.04) when controlling for changes in other spirometric measures of lung function, lung capacities, and roomair arterial blood gas tensions. Finally, LVRS increased the time to first exacerbation in both those subjects with and those without a prior history of exacerbations (P = 0.0002 and P < 0.0001, respectively). Conclusions: LVRS reduces the frequency of COPD exacerbations and increases the time to first exacerbation. One explanation for this benefit may be the postoperative improvement in lung function. Clinical trial registered with www.clinicaltrials.gov (NCT 00000606).

KW - COPD

KW - Exacerbation

KW - LVRS

UR - http://www.scopus.com/inward/record.url?scp=38348998981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38348998981&partnerID=8YFLogxK

U2 - 10.1164/rccm.200708-1194OC

DO - 10.1164/rccm.200708-1194OC

M3 - Article

VL - 177

SP - 164

EP - 169

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 2

ER -